Compile Data Set for Download or QSAR
Report error Found 604 with Last Name = 'currie' and Initial = 'mg'
TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321477(US10183021, Compound I-3)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321478(US10183021, Compound I-200)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321479(US10183021, Compound I-4)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321480(US10183021, Compound I-204)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321481(US10183021, Compound I-11)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321482(US10183021, Compound I-206)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321483(US10183021, Compound I-14)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321484(US10183021, Compound I-213)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321485(US10183021, Compound I-16)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321486(US10183021, Compound I-214)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321487(US10183021, Compound I-19)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321488(US10183021, Compound I-219)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321489(US10183021, Compound I-24)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321490(US10183021, Compound I-221)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321491(US10183021, Compound I-35)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321492(US10183021, Compound I-230)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321493(US10183021, Compound I-39)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321494(US10183021, Compound I-236)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321495(US10183021, Compound I-41)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321496(US10183021, Compound I-239)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321497(US10183021, Compound I-53)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321498(US10183021, Compound I-245)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321499(US10183021, Compound I-54)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321500(US10183021, Compound I-187)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321501(US10183021, Compound I-55)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321502(US10183021, Compound I-300)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321503(US10183021, Compound I-59)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321504(US10183021, Compound I-250)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321505(US10183021, Compound I-67)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321506(US10183021, Compound I-306)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321507(US10183021, Compound I-69)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321508(US10183021, Compound I-453)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321509(US10183021, Compound I-81)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321510(US10183021, Compound I-361)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321511(US10183021, Compound I-85)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321512(US10183021, Compound I-257)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321513(US10183021, Compound I-88)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321514(US10183021, Compound I-258)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321515(US10183021, Compound I-89)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321516(US10183021, Compound I-454)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321517(US10183021, Compound I-90)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321518(US10183021, Compound I-363)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321519(US10183021, Compound I-95)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321520(US10183021, Compound I-364)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321521(US10183021, Compound I-96)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321522(US10183021, Compound I-365)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321523(US10183021, Compound I-101)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321524(US10183021, Compound I-366)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321525(US10183021, Compound I-104)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321526(US10183021, Compound I-455)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 604 total ) | Next | Last >>
Jump to: